PDF(Pubmed)
Abstract：
UNASSIGNED: Impact of B-cell depletion following treatment with Bruton tyrosine kinase-inhibitors (BTKi) on the outcome of SARS-CoV-2 infection in chronic lymphocytic leukemia (CLL) patients remain controversial. We investigated the impact of BTKi on susceptibility and the severity of COVID-19 in Chinese patients with CLL during the first wave of COVID-19 (Omicron variant).
UNASSIGNED: CLL patients (n=171) visiting the Institute of Hematology, Peoples\' Hospital, China (November 15, 2022- January 20, 2023) were included in the study. Seventeen patients receiving BTKi and venetoclax with or without obinutuzumab were excluded. Data from 117 patients receiving treatment with BTKi were collected using a standardized questionnaire through telephone interviews. Thirty-four patients without CLL-specific treatment served as controls. The data was analysed using IBM SPSS Software version 21 and a P value of <0.05 was considered statistically significant.
UNASSIGNED: The median age of patients was 67 years and majority were males (n=100). Treatment with BTKi was not associated with higher incidence of COVID-19 (74% [95% Confidence Interval (CI) 60%, 92%]) versus 74% (CI 48%, 100%) without any treatment (P=0.92). Hypoxemia was reported by 45% (32%, 61%) and 16% (4%, 41%) (P=0.01). BTKi was the only independent risk factor of hypoxemia (Hazard Ratio [HR], 4.22 [1.32, 13.50]; P = 0.02). Five (5.7%) patients with COVID-19 under BTKi required ICU admission; 4 of them died. No ICU admissions/deaths were observed in the control group.
UNASSIGNED: In Chinese patients with CLL and treated with BTKi experienced more severe lung disease and ICU admissions due to COVID-19 than patients without CLL therapy. Frequency of infections with SARS-CoV-2, however, was not different in patients with or without BTKi treatment.
UNASSIGNED: CLL patients (n=171) visiting the Institute of Hematology, Peoples\' Hospital, China (November 15, 2022- January 20, 2023) were included in the study. Seventeen patients receiving BTKi and venetoclax with or without obinutuzumab were excluded. Data from 117 patients receiving treatment with BTKi were collected using a standardized questionnaire through telephone interviews. Thirty-four patients without CLL-specific treatment served as controls. The data was analysed using IBM SPSS Software version 21 and a P value of <0.05 was considered statistically significant.
UNASSIGNED: The median age of patients was 67 years and majority were males (n=100). Treatment with BTKi was not associated with higher incidence of COVID-19 (74% [95% Confidence Interval (CI) 60%, 92%]) versus 74% (CI 48%, 100%) without any treatment (P=0.92). Hypoxemia was reported by 45% (32%, 61%) and 16% (4%, 41%) (P=0.01). BTKi was the only independent risk factor of hypoxemia (Hazard Ratio [HR], 4.22 [1.32, 13.50]; P = 0.02). Five (5.7%) patients with COVID-19 under BTKi required ICU admission; 4 of them died. No ICU admissions/deaths were observed in the control group.
UNASSIGNED: In Chinese patients with CLL and treated with BTKi experienced more severe lung disease and ICU admissions due to COVID-19 than patients without CLL therapy. Frequency of infections with SARS-CoV-2, however, was not different in patients with or without BTKi treatment.
摘要：
■布鲁顿酪氨酸激酶抑制剂（BTKi）治疗后B细胞耗竭对慢性淋巴细胞白血病（CLL）患者SARS-CoV-2感染结局的影响仍存在争议。我们调查了BTKi对中国CLL患者在第一波COVID-19（Omicron变体）中的易感性和COVID-19严重程度的影响。
■CLL患者（n=171）访问血液学研究所，人民医院,中国（2022年11月15日至2023年1月20日）被纳入研究。排除了17例接受BTKi和venetoclax伴或不伴奥比努珠单抗的患者。使用标准化问卷通过电话访谈收集了117名接受BTKi治疗的患者的数据。没有CLL特异性治疗的34例患者作为对照。使用IBMSPSS软件版本21分析数据,P值<0.05被认为具有统计学意义。
■患者的中位年龄为67岁，大多数为男性（n=100）。BTKi治疗与COVID-19的发病率无关(74%[95%置信区间(CI)60%，92%]）与74%（CI48%，100%)未进行任何处理(P=0.92)。据报道，低氧血症占45%(32%，61%)和16%(4%，41%)(P=0.01)。BTKi是低氧血症的唯一独立危险因素(危险比[HR]，4.22[1.32,13.50];P=0.02)。5例(5.7%)BTKi下COVID-19患者需要入住ICU；其中4例死亡。对照组没有ICU入院/死亡。
■在接受BTKi治疗的中国CLL患者中，与未接受CLL治疗的患者相比，COVID-19导致的肺部疾病和ICU入院更严重。然而，SARS-CoV-2感染的频率，有或没有BTKi治疗的患者没有差异。
■CLL患者（n=171）访问血液学研究所，人民医院,中国（2022年11月15日至2023年1月20日）被纳入研究。排除了17例接受BTKi和venetoclax伴或不伴奥比努珠单抗的患者。使用标准化问卷通过电话访谈收集了117名接受BTKi治疗的患者的数据。没有CLL特异性治疗的34例患者作为对照。使用IBMSPSS软件版本21分析数据,P值<0.05被认为具有统计学意义。
■患者的中位年龄为67岁，大多数为男性（n=100）。BTKi治疗与COVID-19的发病率无关(74%[95%置信区间(CI)60%，92%]）与74%（CI48%，100%)未进行任何处理(P=0.92)。据报道，低氧血症占45%(32%，61%)和16%(4%，41%)(P=0.01)。BTKi是低氧血症的唯一独立危险因素(危险比[HR]，4.22[1.32,13.50];P=0.02)。5例(5.7%)BTKi下COVID-19患者需要入住ICU；其中4例死亡。对照组没有ICU入院/死亡。
■在接受BTKi治疗的中国CLL患者中，与未接受CLL治疗的患者相比，COVID-19导致的肺部疾病和ICU入院更严重。然而，SARS-CoV-2感染的频率，有或没有BTKi治疗的患者没有差异。
